SCD inhibition demonstrates a pronounced antileukemic effect in a subset of AML models both in vitro and in vivo and increases sensitivity to conventional chemotherapeutic protocols based on anthracyclines and cytarabine [23]. The gene discussed is SCD; the disease is acute myeloid leukemia.